Free Trial
NASDAQ:CLYM

Climb Bio (CLYM) Stock Price, News & Analysis

Climb Bio logo
$1.25 -0.02 (-1.57%)
As of 05/5/2025 04:00 PM Eastern

About Climb Bio Stock (NASDAQ:CLYM)

Key Stats

Today's Range
$1.25
$1.33
50-Day Range
$1.13
$1.47
52-Week Range
$1.05
$10.86
Volume
124,938 shs
Average Volume
303,223 shs
Market Capitalization
$84.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00
Consensus Rating
Strong Buy

Company Overview

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.

Receive CLYM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Climb Bio and its competitors with MarketBeat's FREE daily newsletter.

CLYM Stock News Headlines

Climb Bio appoints Kim Cobleigh Drapkin, Bo Cumbo to board
REVEALED: Elon’s Secret Master Plan “AGENDA X”
REVEALED: Elon's Secret Master Plan "AGENDA X" For almost 30 years, Elon worked on his master plan in secret. Now, leaked computer code confirms Elon is moments away from launching a revolutionary financial technology… And Silicon Valley insider Jeff Brown says it could hand early investors who missed Tesla, "the ultimate second chance" to get rich.
See More Headlines

CLYM Stock Analysis - Frequently Asked Questions

Climb Bio's stock was trading at $1.80 at the beginning of the year. Since then, CLYM shares have decreased by 30.6% and is now trading at $1.25.
View the best growth stocks for 2025 here
.

Climb Bio, Inc. (NASDAQ:CLYM) announced its quarterly earnings data on Tuesday, March, 25th. The company reported ($0.13) earnings per share for the quarter, beating analysts' consensus estimates of ($0.15) by $0.02.

Climb Bio's top institutional shareholders include Peapod Lane Capital LLC (0.82%) and Bank of New York Mellon Corp (0.10%).
View institutional ownership trends
.

Shares of CLYM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
3/25/2025
Today
5/06/2025
Next Earnings (Estimated)
5/21/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CLYM
Previous Symbol
NASDAQ:CLYM
Fax
N/A
Employees
9
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$10.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+700.0%
Consensus Rating
Strong Buy
Rating Score (0-4)
3.50
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-35,120,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$3.90 per share
Price / Book
0.32

Miscellaneous

Free Float
65,073,000
Market Cap
$84.47 million
Optionable
N/A
Beta
-0.12
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:CLYM) was last updated on 5/6/2025 by MarketBeat.com Staff
From Our Partners